BioAmplified
All protocol guides
AdvancedMetabolic Health13 min read

Metabolic Peptides: GLP-1 and GIP Agonists, In Plain English

The one category here with large randomised trials behind it — what the incretin agonists actually do, what the outcome data shows, and why research powder is a different proposition.

A different category of evidence

Most of this library rests on animal models and practice. The incretin agonists rest on something else entirely: randomised controlled trials with thousands of participants, hard clinical endpoints, and regulatory approval. Semaglutide and tirzepatide are prescription medicines. Everything that follows should be read with that in mind — the question for a reader here is rarely whether the mechanism works.

What incretin hormones do

When you eat, the gut releases hormones called incretins. Two of them matter here:

  • GLP-1 (glucagon-like peptide-1) increases insulin release in a glucose-dependent way, suppresses glucagon, slows the rate at which the stomach empties, and acts on hypothalamic appetite centres.
  • GIP (glucose-dependent insulinotropic polypeptide) also drives insulin release, and appears to influence fat metabolism and appetite regulation.

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both the GIP and GLP-1 receptors. That difference is the main pharmacological distinction between them.

Why they last a week

Native GLP-1 has a half-life of about two minutes — the enzyme DPP-4 destroys it almost immediately. The therapeutic versions are modified in two ways: a structural change that resists DPP-4, and a fatty-acid side chain that binds albumin in the bloodstream, creating a slow-release reservoir. The result is a half-life measured in days rather than minutes, which is what makes weekly dosing possible.

What the trials showed

Semaglutide. The STEP programme produced average body-weight reductions in the range of 15% over 68 weeks in people without diabetes, with the highest dose approaching 17%. The SELECT trial, in people with overweight or obesity and existing cardiovascular disease, showed a reduction in major adverse cardiovascular events — a genuine outcome finding, not a surrogate marker.

Tirzepatide. SURMOUNT-1 reported average reductions exceeding 20% at the highest dose over 72 weeks. SURPASS-2 compared it head-to-head against semaglutide 1 mg and found tirzepatide superior on both HbA1c and weight. Cardiovascular outcome data has since followed.

The comparison worth noting. Higher absolute weight reduction with the dual agonist is consistent across trials. Whether that translates into better long-term outcomes across all populations is still being studied.

The side-effect profile is the tolerability story

Gastrointestinal effects dominate: nausea, vomiting, diarrhoea, constipation and abdominal pain, concentrated during dose escalation. This is why titration is slow and why it is not optional.

Less commonly but importantly: gallbladder disease, and rarely pancreatitis. There is also a clear and often under-discussed effect on body composition — a meaningful share of the weight lost is lean mass, which is why clinical protocols pair these drugs with resistance training and high protein intake.

The contraindications that matter

  • Personal or family history of medullary thyroid carcinoma, or MEN2 syndrome. These are absolute contraindications.
  • Pregnancy. Not for use, and gastric emptying changes mean the drugs need to be stopped well before surgery.
  • Insulin and sulfonylureas, where dose adjustment is required.

Why research powder is a different proposition

The approved products are pen devices engineered to deliver an exact dose from a sealed, sterile cartridge. Research-grade semaglutide is supplied as lyophilised powder requiring reconstitution.

That substitution introduces three specific risks that the pen device exists to eliminate:

  1. Dosing accuracy. Clinical titration steps are stated in milligrams. Converting those to a volume drawn from a home-reconstituted vial is where serious dosing errors happen — and the therapeutic window is not forgiving at higher steps.
  2. Sterility. Every puncture and every step of home reconstitution is a contamination opportunity, and these are injections.
  3. Chain of custody. Cold-chain and identity verification for grey-market powder are not equivalent to what a regulated manufacturer provides.

The single most common serious error in this space is a concentration miscalculation when converting a clinical dose into a volume from a reconstituted vial.

None of that means the mechanism is in question. It means the delivery method is, and the delivery method is what the trials actually tested.

What an honest protocol looks like

The defensible version of this is a clinician-supervised prescription, with:

  • Structured resistance training, to protect lean mass during rapid fat loss.
  • Adequate protein intake, for the same reason.
  • Periodic monitoring of the markers the trials monitored.
  • A plan for what happens at discontinuation — because weight regain after stopping is well documented and expected.

Anything that skips the supervision is not a shortcut version of the trial protocol. It is a different, untested intervention with the same molecule.

Dosing context

What is reported, and by whom

Study & clinical-use amounts

These are the only compounds in this library with dose-finding trials behind them. Semaglutide: 0.25 mg weekly escalating to 1 mg (diabetes) and 2.4 mg (obesity). Tirzepatide: 2.5 mg weekly escalating to 5–15 mg. Retatrutide (investigational): 1–12 mg weekly in phase 2. Metformin, at 500–2,000 mg daily, is the long-studied oral comparator in metabolic research.

In trials, escalation happens on a fixed schedule with monitoring, and patients who cannot tolerate a step go back down. Reproducing a titration schedule from a trial without the monitoring is the most common way people get into trouble with this category.

Community-reported · unverified

Prescribed titration, which community reports closely follow: 0.25 mg weekly for four weeks, then 0.5 mg, then 1 mg and 2 mg for semaglutide (up to 2.4 mg for obesity); 2.5 mg weekly rising through 5, 10, 12.5 and 15 mg for tirzepatide. Community-specific risk: unverified vials. Users describe both under-dosing and accidentally taking several times the intended amount from mislabelled product — the most commonly reported self-inflicted harm in these threads.

These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.

Where the reported amounts come from

Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.

Preclinical & non-clinical data

The incretin mechanism is thoroughly characterised in animals: GLP-1 and GIP receptor agonism slows gastric emptying, increases satiety signalling and improves glucose-dependent insulin release, with additional effects on inflammation and reward pathways in rodents that human data has not confirmed. Semaglutide and tirzepatide are approved medicines; that makes their preclinical literature better supported than most, not more relevant to self-directed use.

Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.

Reported experiences

What people in these communities describe

Public anecdotal reports

This is the only category on the site where the patient communities have years of experience to report, and they describe it in detail: appetite disappearing within days of the first dose, nausea and reflux during each titration step, constipation, fatigue on the days after an increase, and food losing its appeal rather than the person choosing to eat less.

The counterweight shows up just as strongly. Users describe weight returning after stopping, muscle loss alongside fat loss, and — the most specific warning in these communities — research vials of unknown concentration producing wildly different effects from one purchase to the next. A minority describe mood changes that they attribute to the drug itself rather than to eating less. Even in this category, the anecdotes track the trials closely rather than revealing anything the trials missed.

Where these reports come from

These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.

Referenced in this guide

Compounds mentioned

Open a dossier for the mechanism, dosing reference, side effects and the primary sources.

Semaglutide

GLP-1 receptor agonist (Ozempic, Wegovy)

Advanced

Fat Loss & Metabolic

The most thoroughly studied compound on this site — and a prescription medicine.

MetabolicWeight LossPrescription
Open dossier

Tirzepatide

Dual GIP/GLP-1 receptor agonist (Mounjaro, Zepbound)

Advanced

Fat Loss & Metabolic

A dual agonist that outperformed single GLP-1 receptor agonists on weight.

MetabolicWeight LossPrescription
Open dossier
Keep reading

More advanced protocols

AdvancedLongevity

Longevity Protocols: Telomeres, the GH Axis and Mitochondrial Support

The three mechanisms the longevity peptide field is actually built on, what each does and does not have behind it, and why one of them carries a specific theoretical risk.

12 min read

AdvancedProtocols

Mitochondria & Energy: SS-31, MOTS-c and NAD+

Mitochondrial support is the fastest-growing corner of the longevity field. Here is what SS-31, MOTS-c and NAD+ actually have behind them — including the one that is not a peptide at all.

13 min read